- Home
- Medicines
- Cardio-Metabolic
- Dermatology
- Haematology
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- XOLAIR® (omalizumab)
- ATECTURA® BREEZHALER® (indacaterol acetate/mometasone furoate inhalation powder)
- ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)
- Rheumatology
- Therapy Areas
- Cardio-Metabolic
- Dermatology
- Haematology
- About SCD
- Acute myeloid leukaemia (AML)
- Chronic myeloid leukaemia (CML)
- Immune thrombocytopenia
- Myelodysplastic syndromes
- Myelofibrosis
- Thalassaemia
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- Rheumatology
- Events and Webinars
- Cardio-Metabolic
- Dermatology
- Product events and webinars
- Cosentyx® (secukinumab): On demand webinars
- BAD 2021 – Take control early: a complete approach to successful management of skin and joints in patients with moderate to severe plaque psoriasis (PsO)
- Joint clinics: combining dermatology and rheumatology care within your Trust
- Treating plaque psoriasis (PsO) and psoriatic arthritis (PsA) patients with multiple manifestations
- Dermatology 2020: A virtual reality
- On-demand webinars for dermatology patient management
- Xolair® (omalizumab): on-demand webinars
- Cosentyx® (secukinumab): On demand webinars
- Therapy area events and webinars
- Product events and webinars
- Haematology
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- Rheumatology
- Programmes
- Resources and Training
- Cardio-Metabolic
- Dermatology
- Product resources and training
- Cosentyx® (secukinumab) HCP resources for patients
- The You First programme
- XOLAIR® (omalizumab) Resources
- Therapy area resources and training
- Product resources and training
- Haematology
- Neuroscience
- Oncology
- Ophthalmology
- Rare diseases
- Respiratory and Inflammation
- Rheumatology
×
Ask Speakers
×
Medical Information Request
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]